XENE Files NDA for Epilepsy Drug, Falls on Depression Studies’ Setback
Xenon Pharmaceuticals XENE announced that it has submitted a new drug application (NDA) to the FDA for azetukalner,…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS…
Inside Epic’s Rapid-Fire Research Machine
Physicians at the University of Florida noticed an uptick in sinus infections after hurricanes and turned to Epic…
EU Reform Aims to Fast-Track Cancer Drug Access
At the European Society for Medical Oncology (ESMO) Annual Meeting 2025, held recently in Berlin, experts presented an…
ADHD Meds Offer Benefits Far Beyond Core Symptom Relief
Attention-deficit/hyperactivity disorder (ADHD) medications appeared to reduce the risk for suicide, drug misuse, transport incidents, and criminal activity,…
Is the Supplement Ready for Clinical Use?
Popular among bodybuilders, creatine supplementation is gaining traction for its potential use beyond athletic performance. Researchers are exploring…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…